Conference Coverage

Outpatient CAR T infusions feasible using liso-cel


 

REPORTING FROM THE 2018 BMT TANDEM MEETINGS

During the period after leukapheresis while the CAR T cells were in production, patients could have ongoing treatment, but received PET scans to confirm disease before continuing enrollment in the trial and receiving liso-cel. The time from apheresis to product release for the pivotal cohort is now under 21 days, he said.

The study was supported by Juno Therapeutics, which plans to market liso-cel. Dr. Abramson reported ties with Celgene, Gilead, Seattle Genetics, Novartis, and Genentech.

SOURCE: Abramson J et al. Abstract 5.

Pages

Next Article: